Evaluation of Commercial Rubella Immunoglobulin G Avidity Assays

Mubareka, Samira; Richards, Hannah; Gray, Michael J.

doi:10.1128/jcm.01243-06

Cited by 31 publications

(19 citation statements)

References 16 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…The avidity of an antibody can be determined using two distinct approaches. The chaotropic method is based on the chemical dissociation of the antigen-antibody complex by a chaotropic agent, such as urea [12,13,30]. Another approach is based on competitive inhibition of the binding site of the antibody [14,18,19,31,32].…”

Section: Discussionmentioning

confidence: 99%

“…RU were calculated by this standard curve [28]. A relative avidity index (RAI) was calculated for each specimen and was expressed as the percentage of reactivity remaining in the urea-treated wells [13]. The inter-and intra-assay coefficients of variability of the PR3-hn-hr ELISA were 3Á4% and 2Á1% when using PBS, 4Á4% and 2Á9% when using 3 M urea and 4Á2% and 4Á3% when using 5 M urea.…”

Section: Determination Of the Avidity Of Pr3-ancamentioning

confidence: 99%

“…In systemic lupus erythematosus (SLE), high-avidity anti-dsDNA antibodies are associated more closely with renal involvement and/or disease activity than low-or intermediate-avidity anti-dsDNA antibodies [7][8][9][10]. Lastly, determination of the avidity of anti-viral antibodies is useful to differentiate a primary infection from reactivation [11][12][13]. Several published studies have investigated the avidity of MPO-ANCA [14][15][16][17][18][19].…”

Section: Introductionmentioning

confidence: 99%

See 2 more Smart Citations

The avidity of PR3-ANCA in patients with granulomatosis with polyangiitis during follow-up

Kemna

Schlumberger

Paassen

et al. 2016

Clinical and Experimental Immunology

View full text Add to dashboard Cite

SummaryThe objective of this study is to investigate whether the avidity of proteinase-3-anti-neutrophil cytoplasmic antibody (PR3-ANCA) changes during follow-up in different subgroups of patients with granulomatosis with polyangiitis (GPA). We selected 10 patients with renal relapsing GPA, 10 patients with renal non-relapsing GPA and 10 patients with non-renal relapsing GPA. In all patients, an ANCA rise occurred during remission. The avidity was measured using a chaotropic approach at the time of an ANCA rise and at the time of a relapse in relapsing patients or timematched during remission in non-relapsing patients. No difference was observed in the avidity at the ANCA rise between renal relapsing patients [26Á2% (15Á5-47Á5)], renal patients without a relapse [39Á6% (21Á2-63Á4)] and non-renal relapsing patients [34Á2% (21Á6-59Á5)]. In renal relapsing patients, the avidity increased significantly from the moment of the ANCA rise to the relapse [difference 6Á4% (0Á0-17Á1), P 5 0Á0273]. The avidity did not increase after an ANCA rise in renal non-relapsing patients [difference 3Á5 (26Á0 to 10Á1), P 5 0Á6250] or in non-renal relapsing patients [difference 23Á1% (28Á0 to 5Á0), P 5 0Á5703]. The avidity of PR3-ANCA increases after an ANCA rise during follow-up in renal relapsing patients, but not after an ANCA rise in renal patients who remain in remission or in non-renal relapsing patients.

show abstract

Section: Discussionmentioning

confidence: 99%

Section: Determination Of the Avidity Of Pr3-ancamentioning

confidence: 99%

Section: Introductionmentioning

confidence: 99%

See 1 more Smart Citation

The avidity of PR3-ANCA in patients with granulomatosis with polyangiitis during follow-up

Kemna

Schlumberger

Paassen

et al. 2016

Clinical and Experimental Immunology

View full text Add to dashboard Cite

show abstract

“…Among the supplementary tests used to confirm recent primary rubella virus infection, RV-IgG avidity have proved to be very helpful (3,4,5,7,8). Recently, commercial RV-IgG avidity assays have been compared (11). Among the five assays tested, only the Euroimmun and Radim rubella virus IgG avidity assays performed well, demonstrating excellent correlation with the "gold standard" and for this reason were the only ones that were considered reliable.…”

mentioning

confidence: 99%

Development of a Rapid and Convenient Method for Determination of Rubella Virus-Specific Immunoglobulin G Avidity

Vauloup‐Fellous

Ursulet-Diser

Grangeot-Keros

2007

Clin Vaccine Immunol

View full text Add to dashboard Cite

We describe here a rapid and semiautomated method for the determination of rubella virus immunoglobulin G (IgG) avidity with the VIDAS instrument. A total of 153 serum samples from persons with naturally acquired rubella virus infections (n ‫؍‬ 98), from vaccinated persons (n ‫؍‬ 44), and from patients with autoantibodies (n ‫؍‬ 11) were included in this study. The rubella virus-specific IgG avidity assay we developed for the VIDAS instrument was evaluated by comparison with an in-house method. Results obtained with the VIDAS instrument allow considering this method valuable to help confirm or exclude acute primary infection or recent vaccination.Thanks to extensive vaccination programs, rubella virus infection has dramatically decreased, especially in developed countries. However, rubella vaccine coverage is not sufficient throughout the world and rubella cases are still reported. As clinical diagnosis is unreliable, laboratory diagnosis is necessary to confirm acute rubella virus infection. This diagnosis is based on the observation of seroconversion or on the detection of both rubella virus-specific immunoglobulin G (RV-IgG) and RV-IgM. Seroconversion is rarely observed and is not sufficient to confirm acute rubella virus infection. Indeed, as the cutoff of rubella tests is relatively high (10 IU/ml or 15 IU/ml), the first serum sample tested can be considered negative for rubella virus antibodies whereas it may contain trace amounts (below the cutoff) of RV-IgG. Under these conditions, "seroconversion" cannot always be related to acute rubella virus infection. In the same way, if RV-IgM is always detected in acute rubella virus infection, it can also be detected for a long time, especially after vaccination, because of polyclonal stimulation of the immune system and also because of reinfection (1,2,6,12,13,14). Among the supplementary tests used to confirm recent primary rubella virus infection, RV-IgG avidity have proved to be very helpful (3,4,5,7,8). Recently, commercial RV-IgG avidity assays have been compared (11). Among the five assays tested, only the Euroimmun and Radim rubella virus IgG avidity assays performed well, demonstrating excellent correlation with the "gold standard" and for this reason were the only ones that were considered reliable. These commercial tests are processed in microplates and need more than 1 h to be completed. The aim of our study was to develop a rapid and semiautomated RV-IgG avidity method for the VIDAS instrument (bioMérieux, Marcy-l'Étoile, France) that allows single-dose testing. MATERIALS AND METHODSSerum samples. A total of 153 serum samples were included in this RV-IgG avidity study. Ninety-eight samples were collected after naturally acquired rubella virus infection; 19 were from recently acquired infections and were collected between the onset of infection and 1 month after, 5 were collected between 1 and 2 months after the onset of infection, and 74 were collected more than 3 months after the onset of infection (50 were RV-IgG positive and RVIgM negative, and 24...

show abstract

“…The IgG antibody avidity for Toxoplasma gondii, Rubella and CMV was done as per method described by Bodeus & Goubau [12] and NML guide to services (2010) and Mubareka et al [13].…”

Section: Antibody Aviditymentioning

confidence: 99%

Untitled

2015

JHVRV

View full text Add to dashboard Cite

Evaluation of Commercial Rubella Immunoglobulin G Avidity Assays

Cited by 31 publications

References 16 publications

The avidity of PR3-ANCA in patients with granulomatosis with polyangiitis during follow-up

The avidity of PR3-ANCA in patients with granulomatosis with polyangiitis during follow-up

Development of a Rapid and Convenient Method for Determination of Rubella Virus-Specific Immunoglobulin G Avidity

Untitled

Contact Info

Product

Resources

About